Phase II data in locally advanced penile SCC at #ESMO26

Neoadjuvant toripalimab + TIP (n=25): • ORR 84% | pCR 48% • 1y EFS 72% | OS 88% • G3–4 AEs: 84% • HPV+ vs HPV−: pCR 67% vs 33% (NS)
Encouraging efficacy, substantial toxicity. Validation needed.

#PenileCancer